In line with this report, our data indicate a differential response of SF3B1-mutated cells to TAK-243 compared to SF3B1WT, potentially supporting the specificity and applicability of UBA1 inhibition in the development of pharmacological intervention for MDS-SF3B1. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.